ClinicalTrials.gg
CompletedNCT02967237Transition IIUpdated Apr 25, 2022

Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment

A Phase 4 interventional study of insulin glargine (U300) in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 85 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
113th of 175
136 · median 253
Started
2016
with 7 others
Phase 4
103 of 176
2 open now
Registered
138th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 113th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2016, is one of 103 in phase 4, and was the 138th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

The primary objective is to describe the effect of insulin glargine (U300) in type 2 diabetes mellitus (T2DM) patients uncontrolled with their current basal insulin therapy and eligible for basal switching, according to the Physician decision, on glycated hemoglobin (HbA1c) improvement.

Secondary Objectives:

  • Evolution of fasting plasma glucose
  • Evolution of insulin dose and body weight
  • Hypoglycemia incidence
  • Safety
  • Patients satisfaction when they change their insulin for HOE901-U300
Read the detailed description

The total study duration per patient is approximately 28 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetic adult patients treated with basal insulin, with or without oral anti-diabetic agents, with or without glucagon-like peptide-1 (GLP-1) receptor agonist
  • > 7.5%

Exclusion criteria

Exclusion criteria:

  • Patients with high dose of insulin (>1.2 U/kg)
  • Use of prandial insulin
  • Change of dose of antidiabetic drugs within the last 8 weeks
  • Use of systemic during at least 2 weeks in the last 12 weeks

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Insulin glargine (U300)

    Type 2 diabetes mellitus patients uncontrolled with their current basal insulin therapy switched according to the physician decision, to insulin glargine (U300) administered subcutaneously and once daily using a pre-filled pen

    Drug: insulin glargine (U300)

Interventions

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: HOE901; Toujeo

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in HbA1c

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of patients who reach target fasting plasma glucose (90-130 mg/dL)

    Time frame: At Weeks 12 and 24

  2. Percentage of patients with HbA1c <7%, <7.5%, and <8%

    Time frame: At Week 24

  3. Mean change from baseline in HbA1c across HbA1c subgroups category (≤8%, >8 to 9%, and >9%)

    Time frame: Baseline to Week 12 and Week 24

  4. Mean change from baseline in fasting plasma glucose

    Time frame: Baseline to Week 12 and Week 24

  5. Assessment of patient reported outcomes (satisfaction on treatment and perception of hypoglycemia/hyperglycemia) based on the Diabetes Treatment Satisfaction Questionnaire (DTSQ)

    Time frame: Baseline to Week 24

  6. Change in Diabetes Treatment Satisfaction Questionnaire score

    Time frame: Week 24

  7. Number of hypoglycemic events

    Time frame: From inclusion up to Week 24

  8. Number of adverse events

    Time frame: From inclusion up to Week 24

07

Study locations

85 sites
  • Investigational Site Number 250017
    Alencon Cedex, 61014, France
  • Investigational Site Number 250073
    Ales, 30100, France
  • Investigational Site Number 250047
    Amiens Cedex 1, 80054, France
  • Investigational Site Number 250028
    Amilly, France
  • Investigational Site Number 250062
    Bagnols-sur-Cèze, France
  • Investigational Site Number 250093
    Bar le Duc, France
  • Investigational Site Number 250020
    Besancon, 25030, France
  • Investigational Site Number 250081
    BETHUNE Cedex, 62408, France
  • Investigational Site Number 250034
    Bondy, 93143, France
  • Investigational Site Number 250070
    Brest Cedex, 29610, France
  • Investigational Site Number 250022
    Brest, 29000, France
  • Investigational Site Number 250060
    CAHORS Cedex 9, 46005, France
  • Investigational Site Number 250096
    Cannes, 06401, France
  • Investigational Site Number 250037
    CHALONS EN CHAMPAGNE Cedex, 51005, France
  • Investigational Site Number 250072
    Chambery, 73000, France
  • Investigational Site Number 250018
    Cholet, 49300, France
  • Investigational Site Number 250068
    Clermont Ferrand, 63000, France
  • Investigational Site Number 250098
    Cognac, 16112, France
  • Investigational Site Number 250048
    Colmar, 68024, France
  • Investigational Site Number 250088
    Contamines Sur Arve, 74130, France
  • Investigational Site Number 250054
    Coudray, 28630, France
  • Investigational Site Number 250063
    Dijon, 21000, France
  • Investigational Site Number 250013
    Eaubonne, France
  • Investigational Site Number 250095
    Etampes, France
  • Investigational Site Number 250104
    Grenoble, 38043, France
  • Investigational Site Number 250004
    La Roche Sur Yon, 85025, France
  • Investigational Site Number 250002
    La Rochelle Cedex 1, 17019, France
  • Investigational Site Number 250019
    La Seyne sur Mer, France
  • Investigational Site Number 250030
    Lamagistere, 82360, France
  • Investigational Site Number 250103
    LE CHESNAY Cedex, 78157, France
  • Investigational Site Number 250053
    Le Creusot, 71200, France
  • Investigational Site Number 250044
    Le Mans Cedex 9, 72037, France
  • Investigational Site Number 250056
    Lens, France
  • Investigational Site Number 250051
    Lourdes, 65000, France
  • Investigational Site Number 250071
    Mantes La Jolie, France
  • Investigational Site Number 250092
    Marseille, 13006, France
  • Investigational Site Number 250064
    Marseille, 13008, France
  • Investigational Site Number 250089
    Maubeuge, 59600, France
  • Investigational Site Number 250083
    Merignac, 33700, France
  • Investigational Site Number 250035
    Montpellier, 34000, France
  • Investigational Site Number 250061
    Montpellier, 34059, France
  • Investigational Site Number 250010
    Montpellier, 34295, France
  • Investigational Site Number 250008
    Montpellier, France
  • Investigational Site Number 250032
    Mulhouse, France
  • Investigational Site Number 250043
    Nancy, France
  • Investigational Site Number 250005
    NARBONNE Cedex, 11018, France
  • Investigational Site Number 250069
    Nevers, 58000, France
  • Investigational Site Number 250052
    Nimes, 30029, France
  • Investigational Site Number 250059
    Noisy Le Grand, France
  • Investigational Site Number 250058
    Orleans, 45100, France
  • Investigational Site Number 250031
    Paris, 75008, France
  • Investigational Site Number 250105
    Paris, 75012, France
  • Investigational Site Number 250086
    Paris, 75014, France
  • Investigational Site Number 250026
    Paris, 75020, France
  • Investigational Site Number 250084
    PERIGUEUX Cedex, 24019, France
  • Investigational Site Number 250101
    Pessac Cedex, 33604, France
  • Investigational Site Number 250107
    Pointe À Pitre, 97159, France
  • Investigational Site Number 250067
    Pontoise, 95300, France
  • Investigational Site Number 250078
    PRINGY Cedex, 74374, France
  • Investigational Site Number 250042
    Reims Cedex, 51092, France
  • Investigational Site Number 250012
    Roubaix, 59100, France
  • Investigational Site Number 250055
    Roubaix, 59100, France
  • Investigational Site Number 250102
    Saint Brieuc, France
  • Investigational Site Number 250108
    Saint Pierre, 97448, France
  • Investigational Site Number 250065
    Saint-Denis, 93200, France
  • Investigational Site Number 250029
    Saint-Mandé, 94160, France
  • Investigational Site Number 250087
    Seclin, 59113, France
  • Investigational Site Number 250090
    Sete, 34200, France
  • Investigational Site Number 250024
    Strasbourg Cedex 2, 67098, France
  • Investigational Site Number 250006
    Strasbourg, 67000, France
  • Investigational Site Number 250033
    Suresnes, 92150, France
  • Investigational Site Number 250057
    Tarbes, 65013, France
  • Investigational Site Number 250082
    Toulouse Cedex 3, 31076, France
  • Investigational Site Number 250001
    Toulouse, 31000, France
  • Investigational Site Number 250076
    Toulouse, 31027, France
  • Investigational Site Number 250050
    Toulouse, 31100, France
  • Investigational Site Number 250027
    Tours, 37000, France
  • Investigational Site Number 250075
    Tours, 37000, France
  • Investigational Site Number 250041
    Valenciennes, 59322, France
  • Investigational Site Number 250021
    Vandoeuvre Les Nancy Cedex, 54511, France
  • Investigational Site Number 250023
    Venissieux, 69200, France
  • Investigational Site Number 250046
    VICHY Cedex, 03201, France
  • Investigational Site Number 250039
    Vichy, 03200, France
  • Investigational Site Number 250100
    Villeneuve sur Lot, 47300, France
  • Investigational Site Number 250007
    Warloy Baillon, 80300, France
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Jul 2017 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2016
First posted
Nov 18, 2016
Start
Jan 4, 2016
Primary completionActual
Jul 24, 2017
CompletionActual
Jul 24, 2017
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02967237
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 18, 2016
Start date
Jan 4, 2016
Primary completion
Jul 24, 2017
Completion
Jul 24, 2017
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion